Everything below concerns method validation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-23. Numbers and descriptions here follow the published literature rather than marketing material.
Purity values do not necessarily predict biological potency. Net peptide content corrects for counterions such as acetate or trifluoroacetate, water, and residual salts. Impurity thresholds for reporting, identification, and qualification are often set according to regulatory guidance, though specific limits depend on the product class and route of administration. Open questions remain about the toxicological relevance of low-level peptide impurities and about how best to compare results across different analytical platforms. A certificate of analysis should state the methods used and the basis for each reported value.
Peptide purity testing sits within a broader quality control framework. Release testing commonly includes appearance, identity, purity, peptide content, counterion content, water content, and residual solvents. Elemental impurities and microbiological attributes may be examined when relevant to the manufacturing route. Pharmacopoeial monographs and general chapters provide methods and acceptance criteria for some peptides, but many research-grade materials are not covered by such standards. Method validation establishes specificity, linearity, accuracy, precision, range, and robustness for each test.
Handling practices strongly affect measured purity and sample integrity. Many peptides are hygroscopic, susceptible to oxidation, or prone to adsorption on glass and plastic surfaces. Lyophilized powders are typically stored desiccated at -20 °C or below, while solutions may require colder storage and minimized freeze-thaw cycles. Peptides containing cysteine, methionine, or tryptophan can degrade through oxidation or disulfide exchange. Working aliquots reduce repeated exposure to moisture and temperature fluctuations during routine analysis.
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Mass spectrometry provides an identity check that complements chromatographic purity. Electrospray ionization or matrix-assisted laser desorption/ionization measures the mass-to-charge ratio of intact peptides. A match to the expected molecular mass supports correct sequence length and terminal groups. Mass accuracy alone does not prove that every peak in a liquid chromatogram is the target peptide. It also does not directly quantify how much water or counterion remains in a lyophilized powder.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | For lyophilized powder; desiccant and light protection are common. |
| Appearance | White to off-white powder | Visual description alone does not establish purity or identity. |
| Solubility class | Often freely soluble in water | Depends on sequence; hydrophobic peptides may require organic co-solvents. |
| Water content method | Karl Fischer titration | Measures residual moisture that affects net peptide content. |
| Counterion method | Ion chromatography | Quantifies acetate, chloride, trifluoroacetate, and related ions. |
Storage conditions influence purity and therefore testing outcomes. Lyophilized peptides are generally kept cool and dry, while solutions may require refrigeration or freezing depending on sequence and buffer. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis. Testing after storage should use the same validated method as release testing to allow comparison. Stability studies examine how purity changes over time under defined temperature and humidity conditions. Results are compared against baseline data collected at release.
Regulatory frameworks treat peptide purity as part of product quality, though requirements vary by intended use and jurisdiction. Investigational materials may need identity, strength, quality, and purity documentation. Compendial monographs, when available, specify tests and acceptance criteria for certain peptides. For research peptides, oversight is often less prescriptive, and buyers may rely on supplier documentation. Open questions remain about how to standardize impurity reporting across laboratories and how to define purity for complex or modified peptides.
Quality control for peptide products relies on written procedures, batch records, and certificates of analysis. A certificate of analysis typically lists the test methods, specifications, and results for a specific lot. Batch records document synthesis, purification, and testing steps so that results can be traced to process conditions. Method validation establishes accuracy, precision, specificity, linearity, and limits of detection. These records support consistency across lots and allow laboratories to investigate deviations when a specification is not met.
Handling practices influence measured purity. Peptides may adsorb to plastic or glass surfaces, particularly when hydrophobic or positively charged. Weighing hygroscopic powders can introduce water and alter concentration. Dissolving in appropriate solvents and using low-binding tubes can reduce losses. Each laboratory should validate its own procedures because recovery and stability vary with peptide sequence, formulation, and container material. Open questions remain about how best to standardize stability reporting across different peptide classes.
Purity results are only meaningful when linked to a defined sample and method. A certificate of analysis typically lists the analytical technique, column type, gradient, detection wavelength, and integration parameters. It may also report mass confirmation, water content, and counterion composition. For research peptides, laboratories often request the raw chromatogram rather than only a summary percentage. This allows independent review of baseline, peak shape, and any unresolved shoulders that might be missed by a single number.
Regulatory and accreditation expectations depend on the peptide's intended use. Research reagents may be tested with in-house methods, while pharmaceutical development follows validated procedures and pharmacopeial chapters where applicable. Method validation commonly examines accuracy, precision, specificity, linearity, range, and limits of detection and quantitation. Laboratories accredited to ISO/IEC 17025 must document competence, equipment calibration, and uncertainty. Comparing purity results across laboratories remains difficult because different columns, gradients, detection wavelengths, and integration rules can change reported values; open questions include how best to standardize impurity identification and reporting for diverse peptide products.
Quality control for peptides places purity testing within a documented system that includes specifications, test methods, and acceptance criteria. A certificate of analysis typically reports appearance, chromatographic purity, mass confirmation, and storage conditions. System suitability checks, blank injections, and reference standards help ensure that an analytical run is valid. Traceability requires records of sample preparation, instrument settings, and data processing. No single purity threshold applies to all peptides or uses, so specifications are set according to the intended application and risk assessment.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
Peptide purity testing distinguishes several impurity classes. Related substances include truncated sequences, deletion peptides, and diastereomers formed during synthesis, while residual solvents, counterions, and water are not peptide-related but affect mass balance. Aggregates and oxidation products can arise during storage. Each class requires different analytical approaches, and a complete purity profile combines separation, mass measurement, and orthogonal assays. Reporting only a single percentage can obscure which impurities are present, so the profile should name the methods and limits used.
Samarium-151 (151Sm) has a half-life of 94.6 years, undergoing low-energy beta decay, and has a fission product yield of 0.4203% for thermal neutrons and 235U, about 39% of 149Sm's yield. The yield is somewhat higher for 239Pu. Its neutron absorption cross section for thermal neutrons is high at 15200 barns, about 38% of 149Sm's absorption cross section, or about 20 times that of 235U. Since the ratios between the production and absorption rates of 151Sm and 149Sm are almost equal, the two isotopes should reach similar equilibrium concentrations. Since 149Sm reaches equilibrium in about 500 hours (20 days), 151Sm should reach equilibrium in about 50 days. As this is still much shorter than its radioactive half-life, decay will hardly affect this equilibrium while in the reactor. Since nuclear fuel is used for several years (burnup) in a nuclear power plant, the final amount of 151Sm in the spent nuclear fuel at discharge is only a small fraction of the total 151Sm produced during the use of the fuel. According to one study, the mass fraction of 151Sm in spent fuel is about 0.0025 for heavy loading of MOX fuel and about half that for uranium fuel, which is roughly two orders of magnitude less than the mass fraction of about 0.15 for the medium-lived fission product 137Cs. The decay energy of 151Sm is also about an order of magnitude less than that of 137Cs. The low yield, low survival rate, and low decay energy mean that 151Sm has insignificant nuclear waste impact compared to the two main medium-lived fission products 137Cs and 90Sr.
=== Stroke === A retrospective observational study performed using Medicare data found that patients treated with rosiglitazone had a 27% higher risk of stroke compared to those treated with pioglitazone.
Hashim Thaçi (born 24 April 1968) is a Kosovan politician who was the first prime minister of Kosovo (2008–2014) and the foreign minister and deputy prime minister (2014–2016) in the cabinet led by Isa Mustafa. He also served as president of Kosovo from 2016 until his resignation in 2020. Thaçi is from the region of Drenica in Kosovo, which is where the Kosovo Liberation Army (KLA) originated. He studied philosophy in Pristina before moving to Switzerland, where he joined the KLA in 1993. An Albanian nationalist, he rose through the ranks of the KLA to become leader of the most powerful faction by 1999, during the Rambouillet negotiations. He then joined the interim Kosovo administration after the war. Thaçi became leader of the Democratic Party of Kosovo (PDK), which won the largest share of the vote in the 2007 Kosovo elections. In 2008, Thaçi read the declaration of independence of Kosovo and became its first prime minister. In 2016 he was elected president of Kosovo. Thaçi pursued a pro-American policy while in office. In September 2026, Thaçi was convicted by the Kosovo Specialist Chambers' first instance Trial Panel of war crimes in the Kosovo War. Thaçi's defence lawyers stated that they would appeal the decision. In 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office in The Hague filed a ten-count indictment against Thaçi and others, charging them with crimes against humanity and war crimes. To face these charges, Thaçi resigned from the presidency, stating that he did so to "protect the integrity of the presidency of Kosovo".
Eosinophil Eosinophils have large orange granules in their cytoplasm and bi-lobed nuclei. They are found in low amounts in normal blood. Elevated eosinophil counts (eosinophilia) are associated with allergic reactions, parasitic infections, and asthma. Eosinophil counts may be decreased in pregnancy and in response to physiological stress, inflammation or treatment with certain drugs, such as steroids and epinephrine.
== Research == He investigated the derivatives of phenylhydrazines, establishing their relation to the diazo compounds, and he noted the readiness with which they entered into combination with other substances, giving origin to a wealth of hitherto unknown compounds. Of such condensation products undoubtedly the most important are the hydrazones, which result from the interaction with aldehydes and ketones. His observations, published in 1886, that such hydrazones, by treatment with hydrochloric acid or zinc chloride, yielded derivatives of indole, the parent substance of indigo, were a confirmation of the views advanced by von Baeyer on the subject of indigo and the many substances related to it. He next turned to the fuchsine (then called "rosaniline") magenta dyes, and in collaboration with his cousin Otto Fischer, he published papers in 1878 and 1879 which established that these dyes were derivatives of triphenylmethane. Emil Fischer's next research was concerned with compounds related to uric acid. Here the ground had been broken by von Baeyer, but Fischer greatly advanced the field of knowledge of the purines. In 1881 and 1882 he published papers which established the formulae of uric acid, xanthine, caffeine (achieving the first synthesis), theobromine and some other compounds of this group. After purine itself was isolated, a variety of derivatives were prepared, some of which were patented in view of possible therapeutical applications. Fischer is particularly noted for his work on sugars.
Sources: en.wikipedia.org
In Canada, naloxone single-use syringe kits are distributed and available at various clinics and emergency rooms. Alberta Health Services is increasing the distribution points for naloxone kits at all emergency rooms, and various pharmacies and clinics province-wide. All Edmonton Police Service and Calgary Police Service patrol cars carry an emergency single-use naloxone syringe kit. Some Royal Canadian Mounted Police patrol vehicles also carry the drug, occasionally in excess to help distribute naloxone among users and concerned family/friends. Nurses, paramedics, medical technicians, and emergency medical responders can also prescribe and distribute the drug. As of February 2016, pharmacies across Alberta and some other Canadian jurisdictions are allowed to distribute single-use take-home naloxone kits or prescribe the drug to people using opioids. Following Alberta Health Services, Health Canada reviewed the prescription-only status of naloxone, resulting in plans to remove it in 2016, making naloxone more accessible. Due to the rising number of drug deaths across the country, Health Canada proposed a change to make naloxone more widely available to Canadians in support of efforts to address the growing number of opioid overdoses. In March 2016, Health Canada did change the prescription status of naloxone, as "pharmacies are now able to proactively give out naloxone to those who might experience or witness an opioid overdose."
=== Binding mechanism === The receptor for advanced glycation end products (RAGE) is a multiligand member of the immunoglobulin superfamily, originally identified due to its ability to bind advanced glycation end products (AGEs). AGEs accumulate in various chronic conditions such as diabetes and renal failure. However, RAGE also binds other ligands, notably proteins of the S100/calgranulin family, such as EN-RAGE and S100B, which play significant roles in inflammatory processes. RAGE ligands interact with the receptor through its extracellular domain, triggering a cascade of intracellular signaling pathways. These pathways lead to the activation of key transcription factors like nuclear factor kappa B (NF-κB), which is central to the expression of proinflammatory cytokines, adhesion molecules (such as VCAM-1 and ICAM-1), and other mediators of inflammation. Upon binding ligands like EN-RAGE or S100B, RAGE stimulates various inflammatory responses, including endothelial cell activation, mononuclear cell migration, and the production of cytokines such as TNF-α and IL-1β. These interactions between RAGE and its ligands contribute to chronic inflammatory conditions, including atherosclerosis, Alzheimer's disease, and diabetic complications. Inhibiting the RAGE-ligand interaction—through the use of soluble RAGE (sRAGE) or specific antibodies—can suppress these inflammatory responses, offering potential therapeutic strategies.
== History == In 1932, Belgian physiologist Jean La Barre used the word "incretin" for a gut hormone which stimulates the endocrine pancreas including insulin release. He also proposed that such incretins could be used as a treatment for diabetes mellitus.
==== GnRH-associated peptide ==== GnRH-associated peptide (GAP), a 56-amino-acid peptide cleaved from the GnRH precursor, was shown in 1985 to inhibit prolactin secretion in rat pituitary cultures at a potency comparable to dopamine. Its physiological significance in vivo remains uncertain, as results have varied across species.
Sources: en.wikipedia.org
Lyophilized peptides are generally stored desiccated at -20 °C or lower, protected from light and moisture. Solutions are often kept at -80 °C in aliquots to limit freeze-thaw damage. Specific sequences may require different conditions based on oxidation or aggregation risk.
No, high chromatographic purity does not ensure correct three-dimensional structure or biological function. Activity also depends on sequence integrity, post-translational modifications if relevant, and assay conditions. Purity testing measures chemical composition rather than potency.
Counterion content refers to the mass of ions such as acetate, chloride, or trifluoroacetate that remain associated with a peptide after synthesis and purification. These ions can contribute substantially to sample mass and affect net peptide content. Analytical methods for counterions include ion chromatography and capillary electrophoresis.
It measures the relative ultraviolet absorbance area of peptide peaks, usually at 214 nm. It does not directly measure mass, water, counterions, or co-eluting species.